NCT06151691View on ClinicalTrials.gov

Assessment of Early Pancreatic Cancer Prognosis by Minimal Residual Disease Using Multi-omics Approach

Not yet recruitingOBSERVATIONAL
Enrollment

51

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

November 30, 2025

Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
OTHER

Blood collection and Pancreatic ductal adenocarcinoma minimal residual disease detection test

"Blood samples of participants meet the inclusion/exclusion criteria will be collected.~Pancreatic ductal adenocarcinoma minimal residual disease detection test."

Trial Locations (1)

200032

Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University; 270 Dong An Road, Shanghai 200032, China, Shanghai

All Listed Sponsors
collaborator

Shanghai Weihe Medical Laboratory Co., Ltd.

INDUSTRY

lead

Fudan University

OTHER

NCT06151691 - Assessment of Early Pancreatic Cancer Prognosis by Minimal Residual Disease Using Multi-omics Approach | Biotech Hunter | Biotech Hunter